ES2608177T3 - Gemcabeno y derivados para el tratamiento de la pancreatitis - Google Patents

Gemcabeno y derivados para el tratamiento de la pancreatitis Download PDF

Info

Publication number
ES2608177T3
ES2608177T3 ES11810759.8T ES11810759T ES2608177T3 ES 2608177 T3 ES2608177 T3 ES 2608177T3 ES 11810759 T ES11810759 T ES 11810759T ES 2608177 T3 ES2608177 T3 ES 2608177T3
Authority
ES
Spain
Prior art keywords
compound
use according
gemcabeno
administered
pancreatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11810759.8T
Other languages
English (en)
Spanish (es)
Inventor
Charles L. Bisgaier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetaVia Inc
Original Assignee
Gemphire Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics LLC filed Critical Gemphire Therapeutics LLC
Application granted granted Critical
Publication of ES2608177T3 publication Critical patent/ES2608177T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11810759.8T 2010-12-27 2011-12-22 Gemcabeno y derivados para el tratamiento de la pancreatitis Active ES2608177T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061427236P 2010-12-27 2010-12-27
US201061427236P 2010-12-27
PCT/US2011/066736 WO2012092103A1 (en) 2010-12-27 2011-12-22 Gemcabene and derivatives for treating pancreatitis

Publications (1)

Publication Number Publication Date
ES2608177T3 true ES2608177T3 (es) 2017-04-06

Family

ID=45498140

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11810759.8T Active ES2608177T3 (es) 2010-12-27 2011-12-22 Gemcabeno y derivados para el tratamiento de la pancreatitis

Country Status (14)

Country Link
US (1) US8846761B2 (enExample)
EP (2) EP2658536B1 (enExample)
JP (3) JP2014509305A (enExample)
CN (2) CN107648210A (enExample)
AU (1) AU2011352449B2 (enExample)
CA (1) CA2822921C (enExample)
DK (1) DK2658536T3 (enExample)
ES (1) ES2608177T3 (enExample)
HK (1) HK1250484A1 (enExample)
HU (1) HUE031004T2 (enExample)
MX (1) MX337593B (enExample)
PL (1) PL2658536T3 (enExample)
PT (1) PT2658536T (enExample)
WO (1) WO2012092103A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011852A1 (fr) * 1988-06-06 1989-12-14 Showa Denko Kabushiki Kaisha Agent de traitement de la pancreatite ou similaire
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof

Also Published As

Publication number Publication date
US8846761B2 (en) 2014-09-30
JP6207560B2 (ja) 2017-10-04
PT2658536T (pt) 2016-12-22
DK2658536T3 (en) 2017-01-09
HK1250484A1 (zh) 2018-12-21
CN103442707A (zh) 2013-12-11
US20120165411A1 (en) 2012-06-28
HUE031004T2 (en) 2017-06-28
AU2011352449A1 (en) 2013-07-11
EP3170495B1 (en) 2023-04-26
PL2658536T3 (pl) 2017-04-28
JP2016028075A (ja) 2016-02-25
MX337593B (es) 2016-03-11
EP3170495A1 (en) 2017-05-24
CA2822921C (en) 2018-07-17
CA2822921A1 (en) 2012-07-05
EP2658536B1 (en) 2016-10-19
WO2012092103A1 (en) 2012-07-05
JP2018027953A (ja) 2018-02-22
CN107648210A (zh) 2018-02-02
MX2013007310A (es) 2013-10-25
JP2014509305A (ja) 2014-04-17
AU2011352449B2 (en) 2015-06-18
EP2658536A1 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
CN101217952B (zh) 用于预防心血管事件发病的组合物
AU2016349634A1 (en) Treatment of mixed dyslipidemia
ES2487647T3 (es) Composición de combinación que comprende, como ingrediente activo, L-carnitina o propionil-L-carnitina, para la prevención o el tratamiento de la insuficiencia venosa crónica
AU2022320869A1 (en) Treatment of his hyporesponders
ES2282415T3 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y un monoester de acido graso de sacarosa.
ES3027420T3 (en) Pharmaceutical composition for preventing or treating nonalcoholic steatohepatitis
JP6207560B2 (ja) 膵炎を治療するためのゲムカベンおよび誘導体
Gotto Jr et al. Lipid-modifying and antiatherosclerotic drugs
JP4839309B2 (ja) 血栓症治療剤
ES2322455T3 (es) Uso de carnitinas para la prevencion y/o tratamiento de trastornos producidos por la andropausia.
Alfarisi et al. Anti-inflammatory Effects of Trihoney in Hypercholesterolemic Atherosclerotic Rabbits: A Comparative Study With Atorvastatin.
EA020237B1 (ru) Способ снижения смертности от сердечно-сосудистых событий
JP2019519505A (ja) 血管炎症の治療または血管内皮機能の改善におけるトリアセチル−3−ヒドロキシフェニルアデノシンの応用
Wegner et al. Impact of lipid modulation on the intestinal microcirculation in experimental sepsis
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis
Blom et al. New therapeutic developments in lipidology
JP2007039452A (ja) 心血管イベント発症予防用組成物
HK1192147A (en) Gemcabene and derivatives for treating pancreatitis
KR20190076687A (ko) 오메가-3 지방산 및 우르소데옥시콜산(udca)을 포함하는 콜레스테롤 담석 예방 또는 치료용 약학적 조성물 및 이의 제조방법
WO2013083867A1 (es) Prevención y tratamiento de las lesiones renales asociadas a la litiasis renal de la vía urinaria
HK1256960A1 (en) Treatment of mixed dyslipidemia